Eric K. Ashbahian

Array ( [id] => 20554139 [patent_doc_number] => 20260053919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-26 [patent_title] => PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 19/376547 [patent_app_country] => US [patent_app_date] => 2025-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18288 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19376547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20391835 [patent_doc_number] => 20250367310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-04 [patent_title] => MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY [patent_app_type] => utility [patent_app_number] => 19/306247 [patent_app_country] => US [patent_app_date] => 2025-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19306247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20584114 [patent_doc_number] => 20260069704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-12 [patent_title] => MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY [patent_app_type] => utility [patent_app_number] => 19/306199 [patent_app_country] => US [patent_app_date] => 2025-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28056 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19306199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20309181 [patent_doc_number] => 20250326810 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-23 [patent_title] => CYTOKINE COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/254656 [patent_app_country] => US [patent_app_date] => 2025-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19254656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20293917 [patent_doc_number] => 20250319160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-16 [patent_title] => USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 19/248327 [patent_app_country] => US [patent_app_date] => 2025-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19248327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20554162 [patent_doc_number] => 20260053942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-26 [patent_title] => STING AGONIST IMMUNOSTIMULATORY ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 19/222730 [patent_app_country] => US [patent_app_date] => 2025-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19222730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20210140 [patent_doc_number] => 20250279860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 19/088722 [patent_app_country] => US [patent_app_date] => 2025-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19088722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20206342 [patent_doc_number] => 20250276062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-04 [patent_title] => PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 19/088718 [patent_app_country] => US [patent_app_date] => 2025-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19088718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20246900 [patent_doc_number] => 20250295769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-25 [patent_title] => PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 19/088729 [patent_app_country] => US [patent_app_date] => 2025-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18245 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19088729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658543 [patent_doc_number] => 20240425608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY [patent_app_type] => utility [patent_app_number] => 18/828243 [patent_app_country] => US [patent_app_date] => 2024-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18828243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20687694 [patent_doc_number] => 12617829 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-05 [patent_title] => Activatable cytokine polypeptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/601474 [patent_app_country] => US [patent_app_date] => 2024-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 199 [patent_figures_cnt] => 264 [patent_no_of_words] => 42442 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18601474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343703 [patent_doc_number] => 20240252666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY [patent_app_type] => utility [patent_app_number] => 18/436078 [patent_app_country] => US [patent_app_date] => 2024-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19203153 [patent_doc_number] => 20240175052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => Adenovirus armed with bispecific T cell activator [patent_app_type] => utility [patent_app_number] => 18/481833 [patent_app_country] => US [patent_app_date] => 2023-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083158 [patent_doc_number] => 20240109959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE [patent_app_type] => utility [patent_app_number] => 18/481893 [patent_app_country] => US [patent_app_date] => 2023-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201505 [patent_doc_number] => 20240173404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/481213 [patent_app_country] => US [patent_app_date] => 2023-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18958682 [patent_doc_number] => 20240047009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => NANT CANCER VACCINE STRATEGIES [patent_app_type] => utility [patent_app_number] => 18/480149 [patent_app_country] => US [patent_app_date] => 2023-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 247 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18480149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19068586 [patent_doc_number] => 20240103012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => METHODS AND COMPOSITIONS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/476120 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65826 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18476120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447309 [patent_doc_number] => 20240307439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => MULTIFUNCTIONAL IMMUNE CELL THERAPIES [patent_app_type] => utility [patent_app_number] => 18/469948 [patent_app_country] => US [patent_app_date] => 2023-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18469948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19171001 [patent_doc_number] => 20240156975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/464421 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 119699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172561 [patent_doc_number] => 20240158535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => PARATHYROID HORMONE RECEPTOR 1(PTH1R) ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/463087 [patent_app_country] => US [patent_app_date] => 2023-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18463087 [rel_patent_id] =>[rel_patent_doc_number] =>)